Overall responses with ponatinib
| Phase of CML . | CCyR, n (%) . | MMR, n (%) . | MR 4.0, n (%) . | MR 4.5, n (%) . |
|---|---|---|---|---|
| CP (n = 51) | 32/46 (69.6) | 27/46 (58.7) | 19/46 (41.3) | 17/46 (37.0) |
| AP (n = 9) | 3/8 (37.5) | 0/8 (0.0) | 0/8 (0.0) | 0/8 (0.0) |
| BP (n = 18) | 11/16 (68.8) | 10/16 (62.5) | 7/16 (43.8) | 7/16 (43.8) |
| Phase of CML . | CCyR, n (%) . | MMR, n (%) . | MR 4.0, n (%) . | MR 4.5, n (%) . |
|---|---|---|---|---|
| CP (n = 51) | 32/46 (69.6) | 27/46 (58.7) | 19/46 (41.3) | 17/46 (37.0) |
| AP (n = 9) | 3/8 (37.5) | 0/8 (0.0) | 0/8 (0.0) | 0/8 (0.0) |
| BP (n = 18) | 11/16 (68.8) | 10/16 (62.5) | 7/16 (43.8) | 7/16 (43.8) |
In CP, the response was unknown in 5 patients; in AP, in 1 patient; and in BP, in 2 patients.